Thompson Investment Management Inc. Has $316,000 Position in ResMed Inc. (RMD)
Thompson Investment Management Inc. lessened its position in shares of ResMed Inc. (NYSE:RMD) by 15.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,100 shares of the medical equipment provider’s stock after selling 750 shares during the quarter. Thompson Investment Management Inc.’s holdings in ResMed were worth $316,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in ResMed by 17.3% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 42,898 shares of the medical equipment provider’s stock valued at $3,340,000 after buying an additional 6,316 shares during the period. Delta Lloyd Asset Management N.V. purchased a new position in ResMed during the second quarter valued at $6,194,000. Prudential Financial Inc. lifted its holdings in ResMed by 50.5% during the second quarter. Prudential Financial Inc. now owns 131,997 shares of the medical equipment provider’s stock valued at $10,279,000 after purchasing an additional 44,266 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in ResMed by 2.9% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 47,056 shares of the medical equipment provider’s stock valued at $3,665,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in ResMed by 21.4% during the second quarter. Victory Capital Management Inc. now owns 21,597 shares of the medical equipment provider’s stock valued at $1,682,000 after purchasing an additional 3,809 shares in the last quarter. Institutional investors own 58.86% of the company’s stock.
In other ResMed news, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $77.56, for a total transaction of $96,950.00. Following the transaction, the chief financial officer now directly owns 65,941 shares of the company’s stock, valued at $5,114,383.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 118,392 shares of ResMed stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $82.70, for a total transaction of $9,791,018.40. Following the transaction, the director now directly owns 306,615 shares in the company, valued at $25,357,060.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 201,234 shares of company stock worth $16,339,637. Insiders own 1.77% of the company’s stock.
ResMed Inc. (NYSE RMD) traded up $0.73 during trading hours on Friday, hitting $84.98. 649,900 shares of the stock traded hands, compared to its average volume of 869,472. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $11,955.40, a P/E ratio of 29.35, a P/E/G ratio of 1.87 and a beta of 0.79. ResMed Inc. has a 12-month low of $57.45 and a 12-month high of $87.81.
ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. The firm had revenue of $523.66 million for the quarter, compared to the consensus estimate of $506.08 million. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period last year, the firm posted $0.62 earnings per share. analysts expect that ResMed Inc. will post 3 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a $0.35 dividend. This represents a $1.40 annualized dividend and a dividend yield of 1.65%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s dividend payout ratio is currently 56.68%.
Several research firms have issued reports on RMD. J P Morgan Chase & Co increased their price objective on shares of ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a report on Monday, October 30th. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a report on Monday, October 30th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a report on Friday, September 8th. Northland Securities reaffirmed a “sell” rating and set a $55.00 price objective on shares of ResMed in a report on Friday, October 27th. Finally, Barclays PLC increased their price objective on shares of ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a report on Friday, October 27th. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $67.57.
TRADEMARK VIOLATION NOTICE: This news story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://theolympiareport.com/2017/11/17/thompson-investment-management-inc-has-316000-position-in-resmed-inc-rmd.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.